Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Deng, Linyu ^a   Zhang, Jing ^b   Wu, Taixiang ^a   Lawrie, Theresa A ^c  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; HYDROXYUREA; MELPHALAN; METHOTREXATE; VINCRISTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; FOLINIC ACID;

BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TROPHOBLASTIC TUMOR; EARLY TERMINATION OF CLINICAL TRIAL; FEMALE; HYDATIDIFORM MOLE; META ANALYSIS; PREGNANCY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; GESTATIONAL TROPHOBLASTIC DISEASE; HUMANS; HYDATIDIFORM MOLE; HYDROXYUREA; LEUCOVORIN; MELPHALAN; METHOTREXATE; PREGNANCY; TROPHOBLASTIC TUMOR, PLACENTAL SITE; VINCRISTINE;

MLCS; MLOWN;

EID: 84874984511     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005196.pub4     Document Type: Review

References (65)

1. Curry SL, Blessing JA, Disaia PJ, Soper JT, Twiggs LB. A prospective randomised comparison of methotrexate, dactinomycin and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group Study. Obstetrics and Gynecology 1989;73(3 (part 1)):357-62.
2. Alazzam M, Tidy J, Hancock BW, Osborne R, Lawrie T. First-line chemotherapy for low risk gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD007102.pub3]
3. Alazzam M, Tidy J, Osborne R, Coleman R, Hancock B, Lawrie TA. Chemotherapy for recurrent and resistant gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews in press.
4. Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer 1976;38:1373-85.
5. Bagshawe KD. Treatment of trophoblastic tumours. Recent Results Cancer Research 1977;62:192-9.
6. Bagshawe KD, Dent J, Webb J. Hydatidiform mole in England and Wales, 1973-1983. Lancet 1986;ii:673.
7. Bianconi MI, Otero S, Moscheni O, Alvarez L, Storino C, Jankilevich G. Gestational trophoblastic disease: a 21-year review of the clinical experience at an Argentinean public hospital. Journal of Reproductive Medicine 2012;57(7-8):341-9.
8. Bolis G, Bonazzi C, Landoni F, Mangili G, Vergadoro F, Zanaboni F, et al.EMA/CO regimen in high-risk gestational trophoblastic tumour. Gynecologic Oncology 1988;31:439-44.
9. Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, et al.EMA-CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients. Journal of Clinical Oncology 1997;15:2639.
10. Cagayan MS. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. Journal of Reproductive Medicine 2012;57(5-6):231-6.
11. Chauhan A, Dave K, Desai A, Mankad M, Patel S, Dave P. High-risk gestational trophoblastic neoplasia at Gujarat Cancer and Research Institute: thirteen years of experience. Journal of Reproductive Medicine 2010;55(7-8):333-40.
12. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), v 4.0, June 2010. evs.nci.nih.gov/ftp1/CTCAE/About.html. (accessed 12 November 2012).
13. Cyriac S, Rajendranath R, Sridevi V, Sagar TG. Management of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine chemotherapy. Journal of Reproductive Medicine 2011;56(6):219-23.
14. Cyriac S, Rajendranath R, Sridevi V, Sagar TG. Etoposide, cisplatin-etoposide, methotrexate, actinomycin-D as primary treatment for management of very-high-risk gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics 2011;115(1):37-9.
15. Decherney AH, Nathan L. The care and treatment of women. China: Ren-ming Wei-sheng Chu-banshe, 2003.
16. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001:285-312.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
18. Dobson LS, Lorigan PC, Coleman RE, Hancock BW. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. British Journal of Cancer 2000;82:1547-52.
19. Driscoll SG. Trophoblastic growths: morphologic aspects and taxonomy. Journal of Reproductive Medicine 1981;26:2181.
20. Escobar PF, Lurain JR, Singh DK, Bozorgi K, Fishman DA. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine chemotherapy. Gynecological Oncology 2003;91:552-7.
21. Ezoe S. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. International Journal of Environmental Research and Public Health 2012;9:2444-53.
22. Feng F, Xiang Y, Wan X, Geng S, Wang T. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. Annals of Oncology 2011;22:1588-94.
23. FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary and gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics 2009;105:3-4.
24. Fisher R. Genetics. In: Hancock BW, Seckl M, Berkowitz RS, Cole LA editor(s). Gestational Trophoblastic Disease. www.isstd.org/isstd/book.html. 3rd Edition. International Society for the Study of Trophoblastic Diseases, 2009:6-48.
25. Fülöp V, Szigetvári I, Szepesi J, Végh G, Singh M, Berkowitz RS. Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years. Journal of Reproductive Medicine 2012;57(7-8):310-8.
26. Ghaemmaghami F, Modares M, Arab M, Behtash N, Moosavi AZ, Khanafshar N, et al.EMA-EP regimen, as first line multiple agent chemotherapy in high-risk GTT patients (stage II-IV). International Journal of Gynecological Cancer 2004;14(2):360-5.
27. Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematology Oncology Clinics of North America 2012;26:111-31.
28. Hammond CB, Borchert LG, Tyrey L, Creasman WT, Parker RT. Treatment of metastatic trophoblastic disease: good and poor prognosis. American Journal of Obstetrics and Gynecology 1973;115:451-7.
29. Harma M, Harma M, Yurtseven S, Gungen N. Gestational trophoblastic disease in Sanliurfa, southeast Anatolia, Turkey. European Journal of Gynaecologic Oncology 2005;26(3):306-8.
30. Hayashi K, Bracken MB, Freeman DH, Hellenbrand K. Hydatidiform mole in the United States (1970-1977): a statistical and theoretical analysis. American Journal of Epidemiology 1982;115:67-77.
31. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327:557-60.
32. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org.
33. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Good clinical practice consolidated guideline. Federal Register. 1997;62, issue 90:25691-709.
34. Kim SJ, Bae SN, Kim JH, Kim CT, Han KT, Lee JM, et al.Effects of multi agent chemotherapy and independent risk factors in the treatment of high-risk GTT - 25 years experience of KRI-TRD. International Journal of Gynaecology and Obstetrics 1998;60 Suppl 1:85-96.
35. Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. International Journal of Gynecologic Cancer 2001;11:73-7.
36. Kurman RJ, Main CS, Chen HC. Intermediate trophoblast: a distinctive form of trophoblast with specific morphological, biochemical, and functional features. Placenta 1984;5:349-70.
37. Lee C, Smith HO, Kim SJ. Epidemiology. In: Hancock BW, Newlands ES, Berkowitz RS, Cole LA editor(s). Gestational Trophoblastic Diseases. www.isstd.org/isstd/book.html. 3rd Edition. International Society for the Study of Trophoblastic Diseases, 2009:49-96.
38. Lu WG, Ye F, Shen YM, Fu YF, Chen HZ, Wan XY, et al.EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients. International Journal of Gynecological Cancer 2008;18(2):357-62.
39. Lurain JR, Brewer JI. Invasive mole. Seminars Oncology 1982;9:174-80.
40. Lurain JR, Singh DK, Schink JC. Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score > or = 7. Journal of Reproductive Medicine 2010;55(5-6):199-207.
41. Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. American Journal of Obstetrics & Gynecology 2011;January:11-18.
42. Matsui H, Suzuka K, Iitsuka Y, Seki K, Sekiya S. Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecologic Oncology 2000;78(1):28-31.
43. Mazur MT, Szulman AE, Buchsbaum HJ (editors). Choriocarcinoma and placental site trophoblastic tumour (in gestational trophoblastic disease). New York Springer-Verlag. 1987.
44. Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L, Dent J. Developments in chemotherapy for medium and high risk patients with gestational trophoblastic tumours (1979-1984). British Journal of Obstetrics and Gynaecology 1986;93:63-9.
45. Newlands ES, Bower M, Holden L, Short D, Seckl MJ, Rustin GJ, et al.Management of resistant gestational trophoblastic tumors. Journal of Reproductive Medicine 1998;43(2):111-8.
46. Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. Journal of Clinical Oncology 2000;18:854-9.
47. Pastorfide GB, Goldstein DP, Kosasa TS. The use of a radioimmunoassay specific for human chorionic gonadotropin in patients with molar pregnancy and gestational trophoblastic disease. American Journal of Obstetrics and Gynecology 1974;120:1025-8.
48. Popiolek DA, Yee H, Mittal K, Chiriboga L, Prinz MK, Caragine TA, et al.Multiplex short tandem repeat DNA analysis confirms the accuracy of p57(KIP2) immunostaining in the diagnosis of complete hydatidiform mole. Human Pathology 2006;37(11):1426-34.
49. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
50. Schink JC, Singh DK, Rademaker AW, Miller DS, Lurain JR. Etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstetrics & Gynecology 1992;80:817-20.
51. Schorge JO. Contemporary therapy in obstetrics and gynecology. China: Ren-ming Wei-sheng Chu-banshe, 2003.
52. Seckl MJ. Presentation and management of persistent gestational trophoblastic disease (GTD) and gestational trophoblastic tumours (GTT) in the United Kingdom. In: Hancock BW, Seckl MJ, Berkowitz RS, Cole LA editor(s). Gestational trophoblastic disease. www.isstd.org/isstd/book.html. 3rd Edition. International Society for the Study of Trophoblastic Diseases, 2009:277-298.
53. Seckl MJ. Investigation and treatment of patients with persistent gestational trophoblastic disease and gestational trophoblastic tumours/neoplasia in the United Kingdom. In: Hancock BW, Seckl MJ, Berkowitz RS, Cole LA editor(s). Gestational Trophoblastic Disease. www.isstd.org/isstd/book.html. 3rd Edition. International Society for the Study of Trophoblastic Diseases, 2009:335-66.
54. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010;376:717-29.
55. Song HZ. Diagnosis and treatment of trophoblastic tumours. China: Ren-ming Wei-sheng Chu-banshe, 2004.
56. Soper JT, Evans AC, Clark-Pearson DL, Berchuck A, Rodriguez G, Hammond CB. Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. Obstetrics & Gynecology 1994;83(1):113-7.
57. Szulman AE, Surti U. The syndromes of hydatidiform mole: I. cytogenic and morphologic correlations and II morphologic evolution of the complete and partial mole. American Journal Obstetrics and Gynecology 1978;131 and 132:665-71;20-7.
58. Tang Zhao-you. Current Tumourology. China: Ren-ming Wei-sheng Chu-banshe, 2003.
59. Turan T, Karacay O, Tulunay G Boran N, Koc S, Bozok S, et al.Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. International Journal of Gynecological Cancer 2006;16:1432-8.
60. Wang S, An R, Han X, Zhu K, Xue Y. Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences. Gynecologic Oncology 2006;103(3):1105-8.
61. WHO Scientific Group. Gestational trophoblastic disease. Technical Report Series No 692. 1990.
62. Wong LC, Choo YC, Ma HK. Modified Bagshawe's regimen in high-risk gestational trophoblastic disease. Gynecologic Oncology 1986;23:87-93.
63. Zhao Xia-yu. Gestational trophoblastic tumours with EMA/CP regime: an analysis of 22 cases. Journal of Bengbu Medical School 2000;25(5):334-5.
64. Zhao Y, Zhang W, Duan W. Management of gestational trophoblastic neoplasia with 5-fluorouracil and actinomycin D in northern China. Journal of Reproductive Medicine 2009;54(2):88-94.
65. Deng L, Yan X, Zhang J, Wu T. Combination chemotherapy for high-risk gestational trophoblastic tumour. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD005196.pub3]